BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10590282)

  • 1. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
    Geddes A; Thaler M; Schonwald S; Härkönen M; Jacobs F; Nowotny I
    J Antimicrob Chemother; 1999 Dec; 44(6):799-810. PubMed ID: 10590282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
    West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
    Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
    Embil JM; Soto NE; Melnick DA
    Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia.
    Feldman C; White H; O'Grady J; Flitcroft A; Briggs A; Richards G
    Int J Antimicrob Agents; 2001 Mar; 17(3):177-88. PubMed ID: 11282262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
    Tonelli F
    Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
    Donahue PE; Smith DL; Yellin AE; Mintz SJ; Bur F; Luke DR
    Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections.
    Jia B; Lu P; Huang W; Li C; Huang A; Zhou X; Zhang W; Wu G; Zhang G
    Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial.
    Shorr AF; Zadeikis N; Jackson WL; Ramage AS; Wu SC; Tennenberg AM; Kollef MH
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S123-9. PubMed ID: 15712100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.
    Solomkin JS; Reinhart HH; Dellinger EP; Bohnen JM; Rotstein OD; Vogel SB; Simms HH; Hill CS; Bjornson HS; Haverstock DC; Coulter HO; Echols RM
    Ann Surg; 1996 Mar; 223(3):303-15. PubMed ID: 8604912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL; Smith JW; Geckler RW; Wilson SE
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
    Chen Z; Wu J; Zhang Y; Wei J; Leng X; Bi J; Li R; Yan L; Quan Z; Chen X; Yu Y; Wu Z; Liu D; Ma X; Maroko R; Cooper A
    BMC Infect Dis; 2010 Jul; 10():217. PubMed ID: 20663130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.